Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity:
STEP
1 and 4 exploratory analyses
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-10-06
DOI
10.1111/dom.14890
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
- (2022) Domenica M. Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
- (2022) Subodh Verma et al. DIABETES OBESITY & METABOLISM
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
- (2022) John P. H. Wilding et al. DIABETES OBESITY & METABOLISM
- The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials
- (2022) Khaled Alabduljabbar et al. Nutrients
- Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data
- (2021) Sean Wharton et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
- (2020) Mansoor Husain et al. DIABETES OBESITY & METABOLISM
- Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers
- (2020) Jeffrey I. Mechanick et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- SELECT (Semaglutide effects on cardiovascular outcomes in people with overweight or obesity) rationale and design
- (2020) Donna H. Ryan et al. AMERICAN HEART JOURNAL
- Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials
- (2020) Subodh Verma et al. DIABETES OBESITY & METABOLISM
- GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression
- (2020) Mei Qiu et al. Diabetes Therapy
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms by which GLP-1 receptor agonists and SGLT-2 inhibitors reduce cardiovascular risk
- (2019) Abhinav Sharma et al. Canadian Journal of Diabetes
- Cardiovascular risk and obesity
- (2019) C. Cercato et al. Diabetology & Metabolic Syndrome
- Progress and challenges in anti-obesity pharmacotherapy
- (2018) Daniel H Bessesen et al. Lancet Diabetes & Endocrinology
- The Impact of Obesity on the Cardiovascular System
- (2018) Imre Csige et al. Journal of Diabetes Research
- Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation
- (2017) G.A. Bray et al. Obesity Reviews
- Complications of obesity
- (2017) D Kinlen et al. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
- Economic Burden of Obesity: A Systematic Literature Review
- (2017) Maximilian Tremmel et al. International Journal of Environmental Research and Public Health
- 2. Classification and Diagnosis of Diabetes
- (2016) DIABETES CARE
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Medication-related burden and patients’ lived experience with medicine: a systematic review and metasynthesis of qualitative studies
- (2016) Mohammed A Mohammed et al. BMJ Open
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- European Guidelines for Obesity Management in Adults
- (2015) Volkan Yumuk et al. Obesity Facts
- The relationship between anthropometric indexes of adiposity and vascular function in the FATE cohort
- (2013) Billie-Jean Martin et al. Obesity
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started